Award

Effect of Glucagon-like peptide 1 receptor agonist in combination with Insulin on Glycaemic variability and Time-in-range in Diabetic Kidney Disease: a randomised controlled trial

Description: Objective: To compare glucagon-like peptide-1 receptor agonist (GLP-1 RA) plus basal insulin (BGLP) versus basal-bolus (BB) insulin regimens on glycaemic variability (GV) in and time-in-range (TIR) in type 2 diabetes patients with chronic kidney disease (CKD) stage 3-4. Hypothesis: BGLP will be associated with lower GV, improved TIR and lower incidence of hypoglycaemia compared with BB insulin regimens. Design and subjects: Open label, single-centred two group randomised controlled trial in Hong Kong. 100 type 2 diabetes patients with CKD stage 3-4 with HbA1c between 6.5-8.0% will be included. Interventions: GLP-1 RA (dulaglutide) plus insulin degludec once daily (BGLP) or insulin degludec once daily plus 2 or more injections of insulin aspart pre-meals (BB) for 16 weeks with conjunctive use of unblinded real-time continuous glucose monitoring (CGM) for further 10 weeks. Main outcome measure: Difference in % coefficient of variation by blinded CGM at 16 weeks in intervention and control groups. Secondary outcomes: Percentage time-in-ranges, HbA1c, incidence of hypoglycaemia, weight, insulin dose, urine albumin-creatinine ratio, renal function, patient satisfaction at 16 and 26 weeks. Data analysis: Mixed model with repeated measures, with treatment group as fixed effect using a missing at random framework. Expected outcomes: Lower GV in the GLP-1 RA group with greater TIR, lower incidence of hypoglycaemia and weight gain. Purpose and impact: Use of BGLP in this large and significant patient group has the potential to reduce GV while maintaining good glycaemic control, reduce hypoglycaemia and hospitalisations, simply treatment regimens and improve patient quality of life.
Amount: HKD 1,362,000
Funding type: grant
Funder scheme: HMRF - Advanced Medical Research
Start date: 2019-01-01
Institutions: Chinese University of Hong Kong, Department of Medicine & Therapeutics, The Chinese University of Hong Kong
Field: Medicine
Funded outputs count: 0
Funder award ID: 08190596
OpenAlex ID: G7392929549